Udvalget for Humanmedicinske Lægemidler (CHMP) fandt, at fordelene ved Velcade er større end risiciene ved behandling af multipelt myelom.
The Committee for Medicinal Products for Human Use (CHMP) decided that Velcade’ s benefits are greater than its risks for the treatment of multiple myeloma.